Literature DB >> 19294467

Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection.

Alfredo Guglielmi1, Andrea Ruzzenente, Tommaso Campagnaro, Silvia Pachera, Alessandro Valdegamberi, Paola Nicoli, Alessandro Cappellani, Giulio Malfermoni, Calogero Iacono.   

Abstract

BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver tumor. The resectability rate is low because at the time of diagnosis this disease is frequently beyond the limits of surgical therapy. Curative resection (R0) is the most effective treatment and the only therapy associated with prolonged disease-free survival. Based on the gross appearance of the tumor the Liver Cancer Study Group of Japan (LCSGJ) defined three types: mass-forming type (MF), periductal infiltrating type (PI), intraductal growth (IG) type. The prognostic significance of gross type has been demonstrated in Eastern countries, but this issue has not been clarified in Western countries. The aim of this study was to identify the prognostic factors for survival in a group of patients submitted to surgical resection for ICC.
METHODS: Between 1990 and 2007 a total of 81 consecutive patients with ICC were submitted to surgery. Patients with peritoneal carcinomatosis, extensive vascular involvement, or multiple intrahepatic metastases were excluded from surgical resection. Tumors were classified according to TMN stage (6th edition, 2002) and LCSGJ gross type classification. Tumor gross appearance on the cut surface was categorized into the following types according to the classification proposed by the Liver Cancer Study Group of Japan: MF, PI, or IG type.
RESULTS: During the study period 52 patients were submitted to surgical resection with curative intent, whereas in 29 patients surgery was limited to explorative laparotomy. Curative resection (R0) was achieved in 43 patients (83%); and a major hepatic resection was performed in 63% (33/52) of the patients. Extrahepatic bile duct resection was carried out in 36% (19/52) of cases. According to the LCSGJ classification, the MF type was present in 34 patients (65%), the MF + PI type in 13 (25%), the PI type in 3 (6%), and the IG type in 2 (4%). Overall median survival time was 40 months, with a 1-, 3-, and 5-year actuarial survival rates of 83%, 50%, 20%, respectively. Survival was significantly related to the macroscopic gross type, with a median survival of 50 months for patients with the MF type, 19 months for the MF + PI type, 15 months for the PI type, and 17 months for the IG type. At univariate analysis, the macroscopic gross appearance of the tumor, the presence of lymph node metastasis, involvement of extrahepatic bile ducts, the presence of macroscopic vascular invasion, and positive resection margins were significant related to survival. At multivariate analysis, macroscopic vascular invasion and lymph nodes metastases were significant related to survival with hazard ratios of 4.11 and 2.79, respectively. Further statistical analyses were carried out to identify the relation between macroscopic gross type and prognosis. We identified that the MF + PI type tumors were significantly associated with negative prognostic factors, such as the involvement of extrahepatic bile ducts, the presence of lymph nodes metastases, the presence of macroscopic vascular invasion, the presence of perineural invasion, and higher T stage.
CONCLUSIONS: Curative resection of ICC is the only therapy that can achieve long-term survival. The best results were observed in patients who underwent R0 resection for MF tumors without lymph node metastases or vascular invasion. Important predictive factors related to poor survival are MF + PI macroscopic tumor type, lymph node metastases, and vascular invasion. In these patients, other therapeutic approaches (i.e., adjuvant or neoadjuvant therapy) should be evaluated to improve results.

Entities:  

Mesh:

Year:  2009        PMID: 19294467     DOI: 10.1007/s00268-009-9970-0

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  29 in total

1.  A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables.

Authors:  T Okabayashi; J Yamamoto; T Kosuge; K Shimada; S Yamasaki; T Takayama; M Makuuchi
Journal:  Cancer       Date:  2001-11-01       Impact factor: 6.860

2.  Predictive factors for long-term survival in patients with intrahepatic cholangiocarcinoma.

Authors:  T Isa; T Kusano; H Shimoji; Y Takeshima; Y Muto; M Furukawa
Journal:  Am J Surg       Date:  2001-06       Impact factor: 2.565

3.  Report of the 16th follow-up survey of primary liver cancer.

Authors:  Iwao Ikai; Shigeki Arii; Takafumi Ichida; Kiwamu Okita; Masao Omata; Masamichi Kojiro; Kenichi Takayasu; Yasuni Nakanuma; Masatoshi Makuuchi; Yutaka Matsuyama; Yoshio Yamaoka
Journal:  Hepatol Res       Date:  2005-07-18       Impact factor: 4.288

4.  Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period.

Authors:  Hauke Lang; Georgios C Sotiropoulos; Nils R Frühauf; Marco Dömland; Andreas Paul; Eva-Maria Kind; Massimo Malagó; Christoph E Broelsch
Journal:  Ann Surg       Date:  2005-01       Impact factor: 12.969

5.  Histologic bile duct invasion by a mass-forming intrahepatic cholangiocarcinoma.

Authors:  Kazuhiro Hirohashi; Takahiro Uenishi; Shoji Kubo; Takatsugu Yamamoto; Hiromu Tanaka; Taichi Shuto; Osamu Yamasaki; Katsuhiko Horii; Hiroaki Kinoshita
Journal:  J Hepatobiliary Pancreat Surg       Date:  2002

6.  Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.

Authors:  Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

7.  Surgical management of intrahepatic cholangiocarcinoma: a 31-year experience.

Authors:  M J Lieser; M K Barry; C Rowland; D M Ilstrup; D M Nagorney
Journal:  J Hepatobiliary Pancreat Surg       Date:  1998

8.  Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma.

Authors:  Shohachi Suzuki; Takanori Sakaguchi; Yoshihiro Yokoi; Kazuya Okamoto; Kiyotaka Kurachi; Yasuo Tsuchiya; Takuya Okumura; Hiroyuki Konno; Satoshi Baba; Satoshi Nakamura
Journal:  World J Surg       Date:  2002-03-26       Impact factor: 3.352

Review 9.  Current surgical treatment for bile duct cancer.

Authors:  Yasuji Seyama; Masatoshi Makuuchi
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

10.  Surgical outcomes of the mass-forming plus periductal infiltrating types of intrahepatic cholangiocarcinoma: a comparative study with the typical mass-forming type of intrahepatic cholangiocarcinoma.

Authors:  Kazuaki Shimada; Tsuyoshi Sano; Yoshihiro Sakamoto; Minoru Esaki; Tomoo Kosuge; Hidenori Ojima
Journal:  World J Surg       Date:  2007-10       Impact factor: 3.282

View more
  100 in total

1.  Lymphovascular and perineural invasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: a multi-institution analysis.

Authors:  Sarah B Fisher; Sameer H Patel; David A Kooby; Sharon Weber; Mark Bloomston; Clifford Cho; Ioannis Hatzaras; Carl Schmidt; Emily Winslow; Charles A Staley; Shishir K Maithel
Journal:  HPB (Oxford)       Date:  2012-05-22       Impact factor: 3.647

2.  Primary liver cancer: intrahepatic cholangiocarcinoma emerges from the shadows.

Authors:  Susan Tsai; Hari Nathan; Timothy M Pawlik
Journal:  Updates Surg       Date:  2010-08

3.  Tumor emboli from intrahepatic cholangiocarcinoma causing obstructive jaundice.

Authors:  K R Ranjan; A K Pujahari
Journal:  Med J Armed Forces India       Date:  2013-12-16

Review 4.  Staging of intrahepatic cholangiocarcinoma.

Authors:  Sean M Ronnekleiv-Kelly; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2017-02       Impact factor: 7.293

5.  Intrahepatic cholangiocarcinoma: clinicopathological differences between peripheral type and hilar type.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Akira Nakashima; Taijiro Sueda
Journal:  J Gastrointest Surg       Date:  2011-10-20       Impact factor: 3.452

6.  Factors affecting survival after resection of intrahepatic cholangiocarcinoma.

Authors:  Sae Murakami; Tetsuo Ajiki; Taro Okazaki; Kimihiko Ueno; Masahiro Kido; Ippei Matsumoto; Takumi Fukumoto; Yonson Ku
Journal:  Surg Today       Date:  2014-01-23       Impact factor: 2.549

7.  Prediction of the postoperative prognosis of intrahepatic cholangiocarcinoma (ICC): importance of preoperatively- determined anatomic invasion level and number of tumors.

Authors:  Shigeru Marubashi; Kunihito Gotoh; Hidenori Takahashi; Hiroaki Ohigashi; Masahiko Yano; Osamu Ishikawa; Masato Sakon
Journal:  Dig Dis Sci       Date:  2014-01       Impact factor: 3.199

8.  Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study.

Authors:  W F Shen; W Zhong; Q Liu; C J Sui; Y Q Huang; J M Yang
Journal:  World J Surg       Date:  2011-09       Impact factor: 3.352

9.  Patterns and prognostic significance of lymph node dissection for surgical treatment of perihilar and intrahepatic cholangiocarcinoma.

Authors:  Alfredo Guglielmi; Andrea Ruzzenente; Tommaso Campagnaro; Alessandro Valdegamberi; Fabio Bagante; Francesca Bertuzzo; Simone Conci; Calogero Iacono
Journal:  J Gastrointest Surg       Date:  2013-09-19       Impact factor: 3.452

10.  Recurrence after operative management of intrahepatic cholangiocarcinoma.

Authors:  Omar Hyder; Ioannis Hatzaras; Georgios C Sotiropoulos; Andreas Paul; Sorin Alexandrescu; Hugo Marques; Carlo Pulitano; Eduardo Barroso; Bryan M Clary; Luca Aldrighetti; Cristina R Ferrone; Andrew X Zhu; Todd W Bauer; Dustin M Walters; Ryan Groeschl; T Clark Gamblin; J Wallis Marsh; Kevin T Nguyen; Ryan Turley; Irinel Popescu; Catherine Hubert; Stephanie Meyer; Michael A Choti; Jean-Francois Gigot; Gilles Mentha; Timothy M Pawlik
Journal:  Surgery       Date:  2013-03-15       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.